Indoco Remedies · NSE: INDOCO · BSE: 532612
Q2 FY26 results · Jul–Sep 2025
Indoco Remedies reported revenue from operations of ₹484.67 crore (up 12.0% from Q2 FY25) and net loss of ₹9.21 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 484.67 | 432.66 | +12.0% | 437.89 | +10.7% |
| Other income | 0.76 | 1.56 | −51.3% | 1.63 | −53.4% |
| Total income | 485.43 | 434.22 | +11.8% | 439.52 | +10.4% |
| Profit before tax | (13.53) | (4.84) | Loss widened | (36.66) | Loss narrowed |
| Net profit for the period | (9.21) | (10.01) | Loss narrowed | (36.35) | Loss narrowed |
| Attributable to shareholders of the company | (7.93) | (9.57) | Loss narrowed | (35.79) | Loss narrowed |
| EPS, basic (₹) | (1.00) | (1.09) | Loss narrowed | (3.94) | Loss narrowed |
| Net margin (%) | -1.9 | -2.3 | -8.3 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 442.12 | 396.53 | +11.5% | 392.53 | +12.6% |
| Other income | 6.54 | 4.20 | +55.7% | 5.58 | +17.2% |
| Total income | 448.66 | 400.73 | +12.0% | 398.11 | +12.7% |
| Profit before tax | 9.76 | 17.38 | −43.8% | (28.40) | Turned profit |
| Net profit for the period | 15.05 | 12.79 | +17.7% | (28.06) | Turned profit |
| EPS, basic (₹) | 1.63 | 1.39 | +17.3% | (3.04) | Turned profit |
| Net margin (%) | 3.4 | 3.2 | -7.1 |
Consolidated
- Filed with BSE
- 06 Nov 2025, 12:15 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2025, 12:15 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE